Functionalized Bioink Delivering Biomolecules for the Treatment of Craniofacial Diseases

Active, not recruitingOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

October 1, 2026

Conditions
Craniofacial Defects, SubtleSkull DefectCraniosynostoses
Interventions
OTHER

multiomic profiling

2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.

Trial Locations (1)

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC neurochirurgia Infantile, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06533150 - Functionalized Bioink Delivering Biomolecules for the Treatment of Craniofacial Diseases | Biotech Hunter | Biotech Hunter